While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.
One key aspect of the biospecimen market (if not the most important) is the availability and accessibility of the donor pool for testing of both normal, healthy donors and disease state don